Plasma tenoxicam concentrations after single and multiple oral doses

European Journal of Drug Metabolism and Pharmacokinetics
C CrevoisierU C Dubach

Abstract

The pharmacokinetics of single- and multiple-dose administration of tenoxicam 20 mg were evaluated in 8 healthy males. Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h. The area under the plasma concentration-time curve (AUC0-infinity) after a single administration of tenoxicam was 242.5 +/- 73.5 micrograms x h/ml. The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml. Steady-state plasma concentrations of tenoxicam were virtually reached after 10 consecutive daily doses. At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours. AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h. The average fluctuation during multiple-dose administration was 26.8 +/- 8.0% and the accumulation ratio was 5.82 +/- 0.60. Steady-state pharmacokinetic parameters predicted from the first-dose data slightly underestimated observed values, but the results supported the assumption of linear pharmacokinetics during ...Continue Reading

References

Jan 10, 1986·Journal of Chromatography·P HeizmannK Zinapold
Jan 1, 1987·European Journal of Clinical Pharmacology·C J RichardsonR K Verbeeck
Jan 1, 1986·European Journal of Clinical Pharmacology·F F HorberF J Frey
Nov 1, 1985·British Journal of Rheumatology·H A BirdV Wright
Oct 1, 1985·European Journal of Drug Metabolism and Pharmacokinetics·R J FrancisP A Harris
Jan 1, 1985·Clinical Pharmacology and Therapeutics·C J RichardsonR K Verbeeck
Jul 1, 1983·British Journal of Clinical Pharmacology·C AdvenierB Flouvat
Jul 1, 1983·Journal of Pharmaceutical Sciences·W A Colburn
Jul 1, 1982·British Journal of Clinical Pharmacology·A E RitchC J Jones

❮ Previous
Next ❯

Citations

Jun 1, 1994·Journal of Clinical Pharmacy and Therapeutics·M S SalemA A Badwan
Jan 22, 2003·British Journal of Clinical Pharmacology·Ingolf Meineke, Dietrich Türck
May 1, 1991·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S ColliS Nicosia
Dec 5, 2006·Journal of Pharmaceutical and Biomedical Analysis·Iulia SoraAndrei Medvedovici
Jan 1, 1996·Scandinavian Journal of Rheumatology. Supplement·A Barner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

British Journal of Rheumatology
C J Eastmond
Scandinavian Journal of Rheumatology. Supplement
H Fenner
BMJ : British Medical Journal
P Brooks
© 2021 Meta ULC. All rights reserved